Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
450 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06697990 | Cerebrospinal Fluid Immune Microenvironment Mechanism in Anaplastic Lymphoma Kinase Positive Lung Cancer Patients | unknown | Phase 2 | 12 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Nov 20, 2024 | clinicaltrials |
| NCT06395870 | Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | recruiting | Phase 1 | 33 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 |
| Nov 6, 2024 |
| clinicaltrials |
| NCT06656559 | Endoscopic Retrograde Cholangiopancreatography With Radiofrequency Ablation (ERCP-RFA) Combined With Envafolimab and Surufatinib Sequential Therapy for Unresectable Biliary Tract Carcinoma | not yet recruiting | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Oct 24, 2024 | clinicaltrials |
| NCT06141226 | Phase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Capsule and Chemotherapy in the Treatment of Immunoresistant Advanced Non-small Cell Lung Cancer | recruiting | Phase 2 | 148 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06581107 | Validate the Safety and Feasibility of the CT-guided Interventional Robot in Percutaneous Lung Cryablation Procedures | unknown | N/A | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 3, 2024 | clinicaltrials |
| NCT06560528 | Disitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 Overexpression | recruiting | Phase 2 | 40 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 19, 2024 | clinicaltrials |
| NCT06512467 | Donafenib Combine With Sintilimab and HAIC in Neoadjuvant of Resectable Hepatocellular Carcinoma | not yet recruiting | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Jul 22, 2024 | clinicaltrials |
| NCT06506292 | A Phase II Trial of Perioperative Adebrelimab Combined With XELOX in Resectable Locally Advanced Gastric/Gastroesophageal Junction Cancer (GC/GEJC) | recruiting | Phase 2 | 25 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 17, 2024 | clinicaltrials |
| NCT06496789 | Neoadjuvant Serplulimab in Combination With Chemotherapy in Locally Advanced Gastric or Gastro-esophageal Junction Cancer | unknown | Phase 2 | 35 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 11, 2024 | clinicaltrials |
| NCT06492447 | Correlation Study of Serum HER 2 Against HER 2-ADC Drug Efficacy in HER 2 Low-expressing Breast Cancer | unknown | — | 50 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Jul 9, 2024 | clinicaltrials |
| NCT06484764 | Validate the Safety and Feasibility of the CT-guided Interventional Robot in Percutaneous Biopsy Procedure. | completed | N/A | 166 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 5, 2024 | clinicaltrials |
| NCT06487663 | TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant Tumors(TIKET) | recruiting | N/A | 40 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 5, 2024 | clinicaltrials |
| NCT06483386 | Pyrotinib and Subcutaneous Preparation of Trastuzumab Combined With Capecitabine Neoadjuvant Therapy for HER2+ Study of Breast Cancer | not yet recruiting | Phase 2 | 109 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Jul 3, 2024 | clinicaltrials |
| NCT06454448 | Phase Ib/II Clinical Study of Adebrelimab in Combination With Decitabine, Albumin-bound Paclitaxel, and Gemcitabine for the First-line Treatment of Metastatic Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 28, 2024 | clinicaltrials |
| NCT06474481 | Zanubrutinib and G-CHOP in Untreated Intermediate-high Risk Follicular Lymphoma | not yet recruiting | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Jun 25, 2024 | clinicaltrials |
| NCT06454435 | Conversion Therapy of Sintilimab in Combination With Fruquintinib and Chemotherapy Versus Sintilimab and Chemotherpay in Stage IV Gastric Cancer | not yet recruiting | Phase 2 | 158 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 12, 2024 | clinicaltrials |
| NCT06438055 | Clinical Treatment of Refractory Breast Cancer Based on Organoid Drug Sensitivity Results | unknown | N/A | 40 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | May 31, 2024 | clinicaltrials |
| NCT06433362 | CMOEP in the Treatment of Untreated Peripheral T-cell Lymphoma | unknown | Phase 2 | 115 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT05490719 | A Phase II Study of CRT Combined With QL1706 in ESCC Patients | unknown | Phase 2 | 39 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 21, 2024 | clinicaltrials |
| NCT06417567 | The Safety and Effectiveness of NEPA in Preventing Postoperative Nausea and Vomiting After General Anesthesia Gastrointestinal Cancer Surgery: A Single-Center Retrospective Study | recruiting | — | 50 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT06413017 | Nimotuzumab Combined With ICIs for the Treatment of Advanced Liver Cancer After First Line Treatment Failure | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT06409429 | Nimotuzumab Combined With GX as Postoperative Adjuvant Therapy in Pancreatic Cancer | not yet recruiting | Phase 2 / Phase 3 | 146 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 10, 2024 | clinicaltrials |
| NCT06404840 | Evaluating Nimotuzumab in Combination With AG Regimen for Pancreatic Cancer With Liver Metastases : A Prospective, Single-Arm, Phase II Study | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT06405685 | Nimotuzumab Plus AG in Pancreatic Cancer With Liver Metastasis | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT06383559 | Safety and Efficacy of XELOX Combined With Sintilimab and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients | unknown | Phase 2 | 39 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 25, 2024 | clinicaltrials |
| NCT06375486 | Ivonescimab Combined With HAIC for the Treatment of Unresectable Hepatocellular Carcinoma（uHCC）. | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT06375642 | A Single Arm, Single Centered Phase II Trial on the Combination of Adebrelimab, Surufatinib and Irinotecan Liposome-based HAIC in Advanced iCC | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT06370065 | Serplulimab Combined With Bevacizumab Biosimilar and HAIC in Advanced Hepatocellular Carcinoma (HCC) Patients | unknown | Phase 2 | 35 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06363734 | Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial | recruiting | Phase 2 | 32 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 16, 2024 | clinicaltrials |
| NCT05856864 | Cadonilimab in Combination With Ramucirumab for the Treatment of Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy | unknown | Phase 1 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 15, 2024 | clinicaltrials |
| NCT06322563 | Combination of LTC004 and Regorafenib to Treat Patients With Advanced/Metastatic CRC | unknown | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Mar 21, 2024 | clinicaltrials |
| NCT06259058 | Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer | not yet recruiting | Phase 1 / Phase 2 | 96 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Mar 15, 2024 | clinicaltrials |
| NCT06301100 | Single-center, Prospective Study on the Identification and Delineation of Brain and Lung Tumors and At-Risk Organs, and Functional Testing of Surrounding Tissues Based on Dual-Energy CT | unknown | — | 50 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Mar 8, 2024 | clinicaltrials |
| NCT06282120 | Efficacy and Safety of Irinotecan Liposome Injection Combined With 5-FU/LV± Immunotherapy in First-line Gemsitabine + Immunoprogressive Patients With Metastatic Biliary Tract Cancer | unknown | — | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06190652 | Real-world Experience of ICIs Plus Chemotherapy With or Without Radiotherapy for Advanced ESCC.(REICRAE) | completed | — | 728 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 5, 2024 | clinicaltrials |
| NCT06241066 | The Prognostic Value of Tertiary Lymphatic Structure in Esophageal Squamous Cell Carcinoma | completed | — | 359 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 5, 2024 | clinicaltrials |
| NCT06241079 | Multi-institutional Analysis of Survival and Recurrence Patterns of Different Pathological Regression Types After Neoadjuvant Chemoradiotherapy or Radiotherapy for Esophageal Squamous Cell Carcinoma | completed | — | 582 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Feb 5, 2024 | clinicaltrials |
| NCT06233396 | Feasibility Study of Radiation Therapy With Wide Detector 4DCT Scanning for Primary or Metastatic Lung Cancer | completed | — | 33 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT05084677 | Toripalimab Combined With Concurrent Chemoradiotherapy in Cervical Cancer | unknown | Phase 2 | 96 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 18, 2024 | clinicaltrials |
| NCT06208436 | The Survival Outcome of Adjuvant Chemotherapy for Stage I Pancreatic Cancer | unknown | — | 250 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 17, 2024 | clinicaltrials |
| NCT05273827 | Effect of Neoadjuvant Anti-PD-1 Immunotherapy on Perioperative Analgesia and Postoperative Delirium | completed | — | 81 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT06061146 | Tislelizumab Plus Concurrent Chemoradiation in Older With ESCC(TCRTOE) | recruiting | Phase 2 | 136 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT05820906 | Cadonilimab Plus Regorafenib and Gem-Cis Chemotherapy in Advanced Biliary Tract Cancer | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT06143735 | A Study of Efbemalenograstim Alfa Injection for Stage IIIB or IV NSCLC Recieving Moderate-risk Febrile Neutropenia (FN) Chemotherapy Regimen With Risk Factors | unknown | Phase 2 | 99 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT05792228 | A Standardized Intervention to Improve the Management of Chemotherapy-induced Nausea and Vomiting | completed | N/A | 92 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 14, 2023 | clinicaltrials |
| NCT06102746 | Clinical Study of Surufatinib Plus Sintilimab Combined With Chemotherapy in the Treatment of Advanced Gastric Neuroendocrine Carcinoma | unknown | — | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT06102759 | Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin Paclitaxel for Advanced Gastric Cancer After PD-1 Antibody Failed | recruiting | — | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT06102772 | Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin Paclitaxel for Advanced Gastric Cancer | recruiting | — | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT06102785 | Fruquintinib Combined With TAS102 for Advanced Gastric Cancer | recruiting | — | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT04631770 | Mediastinal Lymph Node Dissection Versus Spared Mediastinal Lymph Node Dissection in Stage I GGN NSCLC | recruiting | N/A | 1,362 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 28, 2023 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials